Risultati di uno studio combinato di fase II sul microcitoma polmonare

Translated title of the contribution: Results of a combined phase II study on small cell lung cancer

P. Candido, G. Cavallaro, G. Piatti, E. Bucchioni

Research output: Contribution to journalArticle

Abstract

In two years 62 patients (pts) have been recruited for a phase II study: 57/62 were evaluable since they were affected by pulmonary small cell lung cancer (SGLC). They ware characterized as follows: males (M)/females (F) 44/13. 23 with limited disease (LD), 34 with extended disease (ED). The therapeutic program consisted in induction chemotherapy (phase "A") with 4-iphosphamide 2.5 g/m2 + epirubicin 30 mg/m2 (ist o 3rd day every 21 days, 4 cycles) and in the consolidation chemotherapy (phase "B") with carboplatinum 300 mg/m2 (1st day) + VP-16 120 mg/m2 (1 st to 3 rd day every 21 days, 4 cycles). The LD pts responding after phase "A" have been submitted to thoracic radiotherapy /(RT) 40 Gy concomitant to phase "B". The LD pts completely responding (RC) after the therapeutic program have been submitted to prophylactic panencephalic irradiation (30 Gy). After the phase "A", 75% objective responses (RO) have been recorded (20% RC, 55% partial responses= RP). The responses were independent from the disease extension (p>0.05) and a significant increase of response has been observed in the passage from phase "A" to phase "B" therapy (p=0.039). The mean survival time was 13.5 months (LD vs ED = 15 vs 10 months, p=0.08), with a mean progression time of 6 months (LD vs ED= 7 vs 5 months, p=0.023). This scheme has been shown useful and effective in the therapy of SCLC. Its limitation is due to the fact that two non cross-resistant associated to concomitant RT schedules do not relevantly improve the overall survival. The results are in the range of those obtained by the most credited therapy schemes reported by the international literature.

Original languageItalian
Pages (from-to)105-112
Number of pages8
JournalGIMT - Giornale Italiano delle Malattie del Torace
Volume56
Issue number2
Publication statusPublished - 2002

Fingerprint

Small Cell Lung Carcinoma
Radiotherapy
Consolidation Chemotherapy
Therapeutics
Epirubicin
Ifosfamide
Induction Chemotherapy
Etoposide
Appointments and Schedules
Thorax
Survival Rate
Lung
Survival

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Candido, P., Cavallaro, G., Piatti, G., & Bucchioni, E. (2002). Risultati di uno studio combinato di fase II sul microcitoma polmonare. GIMT - Giornale Italiano delle Malattie del Torace, 56(2), 105-112.

Risultati di uno studio combinato di fase II sul microcitoma polmonare. / Candido, P.; Cavallaro, G.; Piatti, G.; Bucchioni, E.

In: GIMT - Giornale Italiano delle Malattie del Torace, Vol. 56, No. 2, 2002, p. 105-112.

Research output: Contribution to journalArticle

Candido, P, Cavallaro, G, Piatti, G & Bucchioni, E 2002, 'Risultati di uno studio combinato di fase II sul microcitoma polmonare', GIMT - Giornale Italiano delle Malattie del Torace, vol. 56, no. 2, pp. 105-112.
Candido, P. ; Cavallaro, G. ; Piatti, G. ; Bucchioni, E. / Risultati di uno studio combinato di fase II sul microcitoma polmonare. In: GIMT - Giornale Italiano delle Malattie del Torace. 2002 ; Vol. 56, No. 2. pp. 105-112.
@article{83b2c892a1d04350982665d7cfde59cf,
title = "Risultati di uno studio combinato di fase II sul microcitoma polmonare",
abstract = "In two years 62 patients (pts) have been recruited for a phase II study: 57/62 were evaluable since they were affected by pulmonary small cell lung cancer (SGLC). They ware characterized as follows: males (M)/females (F) 44/13. 23 with limited disease (LD), 34 with extended disease (ED). The therapeutic program consisted in induction chemotherapy (phase {"}A{"}) with 4-iphosphamide 2.5 g/m2 + epirubicin 30 mg/m2 (ist o 3rd day every 21 days, 4 cycles) and in the consolidation chemotherapy (phase {"}B{"}) with carboplatinum 300 mg/m2 (1st day) + VP-16 120 mg/m2 (1 st to 3 rd day every 21 days, 4 cycles). The LD pts responding after phase {"}A{"} have been submitted to thoracic radiotherapy /(RT) 40 Gy concomitant to phase {"}B{"}. The LD pts completely responding (RC) after the therapeutic program have been submitted to prophylactic panencephalic irradiation (30 Gy). After the phase {"}A{"}, 75{\%} objective responses (RO) have been recorded (20{\%} RC, 55{\%} partial responses= RP). The responses were independent from the disease extension (p>0.05) and a significant increase of response has been observed in the passage from phase {"}A{"} to phase {"}B{"} therapy (p=0.039). The mean survival time was 13.5 months (LD vs ED = 15 vs 10 months, p=0.08), with a mean progression time of 6 months (LD vs ED= 7 vs 5 months, p=0.023). This scheme has been shown useful and effective in the therapy of SCLC. Its limitation is due to the fact that two non cross-resistant associated to concomitant RT schedules do not relevantly improve the overall survival. The results are in the range of those obtained by the most credited therapy schemes reported by the international literature.",
keywords = "Chemotherapy, Extended disease, Limited disease, Radiotherapy, Survival",
author = "P. Candido and G. Cavallaro and G. Piatti and E. Bucchioni",
year = "2002",
language = "Italian",
volume = "56",
pages = "105--112",
journal = "GIMT - Giornale Italiano delle Malattie del Torace",
issn = "1127-0810",
publisher = "Giornale Italiano Delle Malattie del Torace",
number = "2",

}

TY - JOUR

T1 - Risultati di uno studio combinato di fase II sul microcitoma polmonare

AU - Candido, P.

AU - Cavallaro, G.

AU - Piatti, G.

AU - Bucchioni, E.

PY - 2002

Y1 - 2002

N2 - In two years 62 patients (pts) have been recruited for a phase II study: 57/62 were evaluable since they were affected by pulmonary small cell lung cancer (SGLC). They ware characterized as follows: males (M)/females (F) 44/13. 23 with limited disease (LD), 34 with extended disease (ED). The therapeutic program consisted in induction chemotherapy (phase "A") with 4-iphosphamide 2.5 g/m2 + epirubicin 30 mg/m2 (ist o 3rd day every 21 days, 4 cycles) and in the consolidation chemotherapy (phase "B") with carboplatinum 300 mg/m2 (1st day) + VP-16 120 mg/m2 (1 st to 3 rd day every 21 days, 4 cycles). The LD pts responding after phase "A" have been submitted to thoracic radiotherapy /(RT) 40 Gy concomitant to phase "B". The LD pts completely responding (RC) after the therapeutic program have been submitted to prophylactic panencephalic irradiation (30 Gy). After the phase "A", 75% objective responses (RO) have been recorded (20% RC, 55% partial responses= RP). The responses were independent from the disease extension (p>0.05) and a significant increase of response has been observed in the passage from phase "A" to phase "B" therapy (p=0.039). The mean survival time was 13.5 months (LD vs ED = 15 vs 10 months, p=0.08), with a mean progression time of 6 months (LD vs ED= 7 vs 5 months, p=0.023). This scheme has been shown useful and effective in the therapy of SCLC. Its limitation is due to the fact that two non cross-resistant associated to concomitant RT schedules do not relevantly improve the overall survival. The results are in the range of those obtained by the most credited therapy schemes reported by the international literature.

AB - In two years 62 patients (pts) have been recruited for a phase II study: 57/62 were evaluable since they were affected by pulmonary small cell lung cancer (SGLC). They ware characterized as follows: males (M)/females (F) 44/13. 23 with limited disease (LD), 34 with extended disease (ED). The therapeutic program consisted in induction chemotherapy (phase "A") with 4-iphosphamide 2.5 g/m2 + epirubicin 30 mg/m2 (ist o 3rd day every 21 days, 4 cycles) and in the consolidation chemotherapy (phase "B") with carboplatinum 300 mg/m2 (1st day) + VP-16 120 mg/m2 (1 st to 3 rd day every 21 days, 4 cycles). The LD pts responding after phase "A" have been submitted to thoracic radiotherapy /(RT) 40 Gy concomitant to phase "B". The LD pts completely responding (RC) after the therapeutic program have been submitted to prophylactic panencephalic irradiation (30 Gy). After the phase "A", 75% objective responses (RO) have been recorded (20% RC, 55% partial responses= RP). The responses were independent from the disease extension (p>0.05) and a significant increase of response has been observed in the passage from phase "A" to phase "B" therapy (p=0.039). The mean survival time was 13.5 months (LD vs ED = 15 vs 10 months, p=0.08), with a mean progression time of 6 months (LD vs ED= 7 vs 5 months, p=0.023). This scheme has been shown useful and effective in the therapy of SCLC. Its limitation is due to the fact that two non cross-resistant associated to concomitant RT schedules do not relevantly improve the overall survival. The results are in the range of those obtained by the most credited therapy schemes reported by the international literature.

KW - Chemotherapy

KW - Extended disease

KW - Limited disease

KW - Radiotherapy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0036034030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036034030&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0036034030

VL - 56

SP - 105

EP - 112

JO - GIMT - Giornale Italiano delle Malattie del Torace

JF - GIMT - Giornale Italiano delle Malattie del Torace

SN - 1127-0810

IS - 2

ER -